Search Results < Yale Cancer Center

Yale Cancer Center

223 results

News
Blood-Brain Barrier Protects Against Inflammation but Creates Challenges for Brain Tumor Treatment
When it comes to inflammation, not all organs are created equal. Some—including the brain and the spinal cord—are what’s known as “privileged.” By that, immunologists mean that it is very hard to produce inflammation in them, because these organs have very few immune cells. First, it is difficult for the immune cells to enter them to get in, and then the organs also have inhibitors that turn off the immune cells that do manage to gain entry.
11 May 2022
News
Long-term COVID-19: Tackling Tough Questions About the Body’s Immune Response and Brain Symptoms
As long COVID-19 emerged, here’s what researchers at Yale learned about the body’s immune response and mysterious symptoms affecting the brain.
10 May 2022
News
The Role of Machine Learning Algorithms in Biomedical Discovery
Machine learning algorithms accelerate biomedical research in viral infection, cardiovascular disease, breast cancer and more at Yale’s van Dijk Lab.
10 May 2022
News
Consolidation Durvalumab Alone or Combined With Oleclumab or Monalizumab for Unresectable Stage III NSCLC
In an interim analysis of the phase II COAST trial reported in the Journal of Clinical Oncology, Roy S. Herbst, MD, PhD, FACP, FASCO, and colleagues found that consolidation durvalumab in combination with the anti-CD73 antibody oleclumab or anti-NKG2A antibody monalizumab both improved objective response rate and progression-free survival vs durvalumab alone among patients with unresectable stage III non–small cell lung cancer (NSCLC) without disease progression following definitive platinum-based concurrent chemoradiotherapy.
Source: ASCO Post
5 May 2022
News
Pembrolizumab With or Without Chemo Has Increased Efficacy With Increasing PD-L1 Expression in HNSCC
Pembrolizumab with or without chemotherapy resulted in a numerically longer overall survival benefit vs cetuximab plus chemotherapy in patients with head and neck squamous cell carcinoma and a PD-L1 combined positive score (CPS) between 1 and 19, but did not improve survival in the subset with a PD-L1 CPS of less than 1.
Source: OncLive
4 May 2022
News
Yale Research Looks at Mutations in Tumor Genes to Tell Us What Causes Cancer
By looking at which mutations in our genes are likely to cause particular cancers, researchers at Yale Cancer Center can tell which are more preventable and which are more related to factors we can’t control, such as aging.
Source: New Haven Register
2 May 2022
News
Durvalumab Combinations Push the Response Envelope in Unresectable NSCLC
share to facebook share to twitter share to linkedin email article The packaging and vial of Imfinzi over a computer rendering of lung cancer. Patients with unresectable stage III non-small cell lung cancer (NSCLC) had a higher response rate and better progression-free survival when novel targeted agents were added to treatment with durvalumab (Imfinzi), a phase II randomized trial showed.
Source: Medpage Today
2 May 2022
News
Roundtable Discussion: Petrylak Examines Challenges From Updated Treatments in Metastatic Prostate Cancer
Dr. Daniel Petrylak moderates a roundtable discussion on metastatic prostate cancer.
Source: Targeted Oncology
28 Apr 2022
News
Durvalumab Plus Oleclumab or Monalizumab Induces Increased Response Rates in NSCLC
Consolidation therapy with durvalumab and either oleclumab or monalizumab showed increased clinical benefits in patients with unresectable stage III non–small cell lung cancer.
Source: OncLive
28 Apr 2022
News
How to Tell whether a Cancer Is Caused by Plain Bad Luck
Cancer results from a combination of spontaneous mutations that arise with age—just call it “bad luck”—and environmental exposures to carcinogens such as tobacco, ultraviolet light or viruses. But the question of the relative contribution of luck—compared with more explicit causes—has generated vigorous debate for years.
Source: Scientific American
26 Apr 2022
News
Yale Study Identifies Causes of Cancers
A team of Yale-led researchers can now quantify the factors causing changes in the DNA that contribute most to cancer growth in tumors of most major tumor types. Their molecular analysis approach brings clarity to a longstanding debate over how much control humans have over developing cancer over time.
26 Apr 2022
News
Daniel P. Petrylak, MD, Reviews Ongoing Clinical Trials in Bladder Cancer
At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Daniel P. Petrylak, MD, spoke about ongoing trials may hold promise for the treatment of patients with bladder cancer.
Source: Cancer Network
22 Apr 2022
News
New Yale Center Will Focus on Infection and Immunity
The center will have an ambitious goal: to produce better diagnoses, treatments, and ultimately cures for an array of diseases. It will also work toward vaccine development, based on Iwasaki’s pioneering work showing that vaccines directed toward the mucosa might provide better protection than systemic vaccination.
21 Apr 2022
News
Pembrolizumab/Lenvatinib Plus Chemo May Represent “Powerful” Option for NSCLC
Roy S. Herbst, MD, PhD, discusses the rationale for exploring immunotherapy/TKI combinations like pembrolizumab plus lenvatinib in patients with non–small cell lung cancer, and outlined the different efforts that comprise the LEAP clinical trial program.
Source: OncLive
20 Apr 2022
News
Team Effort Among Yale Pathologists, Smilow Oncologists Leads to Rapid Diagnosis and Treatment
Yale pathologists and Smilow oncologists team to provide expert diagnosis and treatment to a young patient who arrived at the hospital with severe complications.
13 Apr 2022
News
Yale Investigators to Study How Stress Drives Renal Cell Cancer
Rachel Perry, PhD, received the R01 grant. Drs. Andrew Wang and Adebowale Adeniran are co-investigators.
11 Apr 2022
News
American Society for Investigative Pathology to Honor Qin Yan, PhD, with 2023 Outstanding Investigator Award
The American Society for Investigative Pathology has announced it will honor Qin Yan, PhD, Associate Professor of Pathology at Yale School of Medicine, with its 2023 Outstanding Investigator Award.
11 Apr 2022
News
Priming the Pump: WHRY and Akiko Iwasaki Take the Long View on Research
Dr. Akiko Iwasaki’s efforts to create a nasal spray vaccine that generates an effective immune response to COVID-19 evolved from work first sponsored by Women’s Health Research at Yale almost two decades ago.
11 Apr 2022
News
Giving Immunotherapy before Surgery Prevents Lung Cancer from Returning, Study Says
Giving the immunotherapy Opdivo, made by Bristol Myers Squibb, to lung cancer patients before surgery can help prevent the disease from coming back, a new study says.
Source: Stat
11 Apr 2022
News
Outcomes With Pembrolizumab, Pembrolizumab/Chemotherapy, and Cetuximab/Chemotherapy by PD-L1 CPS in Recurrent/Metastatic Head and Neck Cancer
In a post hoc analysis of the KEYNOTE-048 trial reported in the Journal of Clinical Oncology, Barbara Burtness, MD, and colleagues found that survival results with pembrolizumab and pembrolizumab/chemotherapy vs cetuximab/chemotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma and a PD-L1 combined positive score (CPS) of 1 to 19 supported CPS as a predictive factor for benefit of pembrolizumab and pembrolizumab/chemotherapy.
Source: The ASCO Post
5 Apr 2022